Clinical Trial Detail

NCT ID NCT02930109
Title A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Prescient Therapeutics, Ltd.
Indications

acute lymphoblastic leukemia

acute myeloid leukemia

chronic myeloid leukemia

Therapies

Cytarabine + Triciribine

Age Groups: adult senior

No variant requirements are available.